Thursday, March 21, 2013
BioMarin Pharmaceutical Inc., of San Rafael, Calif., reported results from a Phase I/II trial, dubbed POM-001, testing BMN-701, a fusion protein of insulin-like growth factor-2 and acid alpha-glucosidase, for late-onset Pompe disease.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.